Oily core/amphiphilic polymer shell nanocapsules change the intracellular fate of doxorubicin in breast cancer cells

J Mater Chem B. 2019 Oct 23;7(41):6390-6398. doi: 10.1039/c9tb00587k.

Abstract

The aim of this work was to develop and test the in vitro biological activity of nanocapsules loaded with a doxorubicin (DOX) free base dissolved in a core of castor oil shelled by poly(methyl vinyl ether-co-maleic anhydride) conjugated to n-octadecylamine residues. This system was stable and monodisperse, with a hydrodynamic diameter of about 300 nm. These nanocapsules changed the intracellular distribution of DOX, from the nuclei to the cytoplasm, and exhibited higher toxicity towards cancer cells - 4T1 and MCF-7 - and significantly lower toxicity towards normal cells - NIH-3T3 and MCF-10A - in vitro. In conclusion, these nanocapsules are suitable DOX carriers, which remain to be studied in in vivo tumor models.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Castor Oil
  • Cell Line
  • Cell Line, Tumor
  • Cell Nucleus
  • Cytoplasm
  • Doxorubicin / metabolism*
  • Doxorubicin / toxicity
  • Drug Carriers / chemistry*
  • Drug Carriers / standards
  • Humans
  • MCF-7 Cells
  • Mice
  • NIH 3T3 Cells
  • Nanocapsules / chemistry*

Substances

  • Drug Carriers
  • Nanocapsules
  • Castor Oil
  • Doxorubicin